The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti– Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC Yueping.

Slides:

Advertisements

Similar presentations

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB Martin J. Edelman, MD, Lydia.

Advertisements

Su K. Metcalfe, MD, MPH, Michael T

Overexpression of β-Catenin and Cyclin D1 is Associated with Poor Overall Survival in Patients with Stage IA–IIA Squamous Cell Lung Cancer Irrespective.

A non-endoscopic device to sample the oesophageal microbiota: a case-control study Daffolyn R Fels Elliott, MD, Alan W Walker, PhD, Maria O'Donovan, MD,

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Volume 152, Issue 4, Pages e7 (March 2017)

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis Sarah Cargnin, PhD,

Exome-Wide Association Study Identifies Low-Frequency Coding Variants in 2p23.2 and 7p11.2 Associated with Survival of Non–Small Cell Lung Cancer Patients

Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H

Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology Steven L. Taylor, BSc, Lex E.X. Leong, PhD, Jocelyn.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

SC17.02 Lung Cancer in China: Challenges and Perspectives

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Microbiome differences in disease severity and stable or exacerbation visits. Microbiome differences in disease severity and stable or exacerbation visits.

Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Arjun Pennathur, MD, Liqiang Xi, MD, Virginia R. Litle, MD, William E

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With.

Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer

Molecular Subtypes of Non-muscle Invasive Bladder Cancer

Co-Overexpression of Cyclooxygenase-2 and Microsomal Prostaglandin E Synthase-1 Adversely Affects the Postoperative Survival in Non-small Cell Lung Cancer

EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR Shang-Gin Wu, MD, Yao-Wen Kuo, MD, Yih-Leong Chang,

Effect of First-Line Treatment on Myeloid-Derived Suppressor Cells’ Subpopulations in the Peripheral Blood of Patients with Non–Small Cell Lung Cancer

Karin J. C. Sanders, MD, Lizza E. Hendriks, MD, Esther G. C

Alterations in the Gut Microbiota Associated with HIV-1 Infection

Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Lower airway microbiota and mycobiota in children with severe asthma

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non–Small-Cell Lung Cancer Jung-Jyh Hung, MD,

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Li Xia, David S. Schrump, Jeffrey C. Gildersleeve

Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis Elizabeth A. David, MD, Megan E.

Alterations of Gut Microbiome in Rheumatoid Arthritis

Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External.

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial Kenneth S. Thress, PhD, Vivien.

Volume 19, Issue 3, Pages (March 2016)

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Presented by Jacob Miller

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer Tateaki Naito, MD, PhD, Fumihiro Tanaka, MD, PhD, Akira Ono, MD,

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter.

Thoracoscopic Lobectomy Produces Long-Term Survival Similar to That with Open Lobectomy in Cases of Non–Small Cell Lung Carcinoma: A Propensity-Matched.

Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial Luis Paz-Ares, MD, Vera Hirsh, MD, Li Zhang, MD,

Does Lymph Node Metastasis Have a Negative Prognostic Impact in Patients with NSCLC and M1a Disease? Chenyang Dai, MD, Yijiu Ren, MD, Dong Xie, MD, PhD,

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

It’s All in the “Swerve of the Curve”

Pulmonary Resection for Metastases from Colorectal Cancer

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

Altered mycobiota and bacterial-fungal correlation in AS patients receiving different therapeutic regimens. Altered mycobiota and bacterial-fungal correlation.

A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104 Ramaswamy Govindan, MD, Xiaofei.

(A and B) Unweighted (A) and weighted (B) UniFrac clustering of three 16S rRNA hypervariable regions using fragment insertion SATé-enabled phylogenetic.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

V. Lazarevic, S. Manzano, N. Gaïa, M. Girard, K. Whiteson, J. Hibbs, P

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013 Chris Dickhoff, MD, Max Dahele, MBChB., PhD,

Robert Comis, MD, The Passing of a “Lung Man”

Journal of Thoracic Oncology

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti– Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC Yueping Jin, MD, PhD, Hui Dong, PhD, Liliang Xia, PhD, Yi Yang, MD, Yongqiang Zhu, MS, Yan Shen, BS, Huajun Zheng, PhD, Chengcheng Yao, MS, Ying Wang, PhD, Shun Lu, MD, PhD Journal of Thoracic Oncology Volume 14, Issue 8, Pages 1378-1389 (August 2019) DOI: 10.1016/j.jtho.2019.04.007 Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Study scheme. Journal of Thoracic Oncology 2019 14, 1378-1389DOI: (10.1016/j.jtho.2019.04.007) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Comparison of gut microbiota diversity between responder (R) and nonresponder (NR) groups. (A,B) Shannon index and Inverse Simpson index in R (n = 13) and NR (n = 12) at baseline (A) and T1 timepoint (B), respectively. Statistical analysis was performed by Mann-Whitney test. **p < 0.01, * p < 0.05. (C) Kaplan-Meier (K-M) plot of the progression-free survival (PFS) by Log-rank test in patients with high diversity and low diversity (Shannon cutoff value: 2.31). (D) Principal coordinates analysis of gut microbiota at baseline. Red legends represented NR and blue legends represented R. Statistical analysis was performed by multivariate analysis of variance test. p = 0.001. Journal of Thoracic Oncology 2019 14, 1378-1389DOI: (10.1016/j.jtho.2019.04.007) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Comparison of gut microbiota composition between responders (R) and nonresponders (NR). (A) Heatmap of seven bacterial genera with statistically differential abundance in R (n = 13) and NR (n = 12) at baseline. (B) Histogram of two representative differentially abundant genera at baseline. (C) Histogram of Bifidobacterium longum and Prevotella copri at baseline (left) and T1 timepoint (right). Statistical analysis was performed by Mann-Whitney test. **p < 0.01, * p < 0.05. Journal of Thoracic Oncology 2019 14, 1378-1389DOI: (10.1016/j.jtho.2019.04.007) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

Figure 4 Gut microbiota profiles remain stable during the treatment. (A) Dynamics of Shannon diversity index in longitudinal samples (left) and in paired samples at baseline and T1 timepoint (middle) or progression timepoint (right). (Blue dot: responders [R], red dot: nonresponders [NR]). Statistical analysis was performed by Wilcoxon matched-pairs signed rank (middle and right) or Kruskal-Wallis (left) tests. (B) Stacked bar plot of phylogenetic composition at genus level in paired samples (left: baseline, right: progression). (C) Principal coordinate analysis of 10 individuals sampling at different timepoints using unweighted Unifrac distance. Each symbol represented one individual patient. (D,E) Multiple comparison of representative bacteria at phylum (D) and genus (E) levels by Kruskal-Wallis test. p > 0.05 for all tests. Journal of Thoracic Oncology 2019 14, 1378-1389DOI: (10.1016/j.jtho.2019.04.007) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

Figure 5 Correlation analysis of Shannon diversity index with peripheral immune signatures. (A,B) Spearman correlations between Shannon diversity index and memory CD8+ T cell subsets. (C) Spearman correlations between Shannon diversity index and natural killer (NK) cell subsets. (D) Comparison of immune parameters between high-diversity group and low-diversity group. (black bar: high diversity; grey bar: low diversity). Statistical analysis was performed by Spearman correlation (A, B, and C) or Mann-Whitney (D) tests. **p < 0.01, * p < 0.05. Journal of Thoracic Oncology 2019 14, 1378-1389DOI: (10.1016/j.jtho.2019.04.007) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions